NephroDI Therapeutics
PrivateLast Round
Series A
Jun 20, 2024
Total Funding Raised
$7.85M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
NephroDI Therapeutics operates in Healthcare & Life Sciences and is based in Philadelphia, Pennsylvania. Its latest recorded funding round was a Series A round in June 2024.
NephroDI Therapeutics is a biotechnology company developing novel kidney-targeted AMPK activators for the treatment of congenital nephrogenic diabetes insipidus.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NephroDI Therapeutics Comparables
Compare NephroDI Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ePurines, Inc. | 68% | |
| Renibus Therapeutics | 65% | |
| Travere Therapeutics Inc | 61% |
For institutional investors. Book with your work email.
NephroDI Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 20, 2024 | ||||
| Grant | Sep 1, 2022 | ||||
| Seed | Feb 23, 2021 | ||||
| Grant | Sep 15, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NephroDI Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Xontogeny | Seed |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| Sound Bioventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 73% MoM.
- Apr 17, 2026
Monthly visitors increased 175% MoM, reaching 1.4K.
For institutional investors. Book with your work email.
NephroDI Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NephroDI Therapeutics's valuation, stock price, and market status.
Is NephroDI Therapeutics a public or private company?
NephroDI Therapeutics is a private company.
What is the current stock price of NephroDI Therapeutics?
NephroDI Therapeutics is a private company, so its shares have no public market price. Caplight tracks NephroDI Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NephroDI Therapeutics worth (valuation)?
Valuation information for NephroDI Therapeutics is not publicly available.
Can I buy NephroDI Therapeutics stock?
NephroDI Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NephroDI Therapeutics's last funding round?
NephroDI Therapeutics's most recent funding round was Series A on June 20, 2024.
Who are the main investors in NephroDI Therapeutics?
Key investors in NephroDI Therapeutics include Xontogeny, Sound Bioventures.
Will NephroDI Therapeutics IPO soon?
No public IPO plans have been announced for NephroDI Therapeutics.
How can I track NephroDI Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NephroDI Therapeutics's shares on secondary markets.